Robbins LLP Reminds Jasper Therapeutics, Inc. Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Against JSPR

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, Briquilimab, during the period from November 30, 2023, to July 3, 2025 [1][2]. Allegations - The lawsuit claims that Jasper Therapeutics failed to disclose critical information, including: - Lack of necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations [2]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects [2]. - Heightened likelihood of disruptive cost-reduction measures [2]. - Overstated business and financial prospects, as well as the clinical and commercial prospects of Briquilimab [2]. Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3]. Class Action Participation - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can remain absent class members if they choose [4]. Firm Background - Robbins LLP is noted for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].